US 12,357,635 B2
Nanocarriers and their processing for diagnostics and therapeutics
Qian Chen, Barrington, RI (US); Yupeng Chen, Sharon, MA (US); Hongchuan Yu, Providence, RI (US); and Michael G. Ehrlich, Providence, RI (US)
Assigned to Rhode Island Hospital, Providence, RI (US)
Filed by Rhode Island Hospital, Providence, RI (US)
Filed on Jan. 10, 2020, as Appl. No. 16/739,864.
Application 16/739,864 is a continuation of application No. 15/687,289, filed on Aug. 25, 2017, granted, now 10,555,948.
Application 15/687,289 is a continuation of application No. 14/659,071, filed on Mar. 16, 2015, granted, now 9,775,842, issued on Oct. 3, 2017.
Claims priority of provisional application 62/113,335, filed on Feb. 6, 2015.
Claims priority of provisional application 61/953,495, filed on Mar. 14, 2014.
Prior Publication US 2020/0375991 A1, Dec. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/51 (2006.01); A61K 31/519 (2006.01); A61K 47/69 (2017.01); A61K 49/00 (2006.01); C12Q 1/6881 (2018.01); C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01); G01N 33/68 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/519 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0092 (2013.01); A61K 9/08 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 47/6949 (2017.08); A61K 49/0095 (2013.01); C12Q 1/6881 (2013.01); C12Q 1/6883 (2013.01); C12Q 1/6886 (2013.01); G01N 33/6893 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); C12N 15/1138 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); C12Y 304/24812 (2013.01); G01N 2800/102 (2013.01); Y02A 50/30 (2018.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating a disease or disorder of the central nervous system comprising administration of an effective amount of a nanopiece, wherein said nanopiece comprises a compound of Formula I or Formula II or a combination thereof, and a nucleic acid:

OG Complex Work Unit Chemistry
wherein,
X is CH or N;
R2 is hydrogen or a linker group;
Y is absent when R2 is hydrogen or is an amino acid side-chain, amino acid or polypeptide; and
R1 is hydrogen or C1 to C10 alkyl; and
wherein the nanopiece has a size in at least one dimension between 1 nm and 30 nm,
wherein a ratio of the compound to nucleic acid ranges from 4.4 to 30 μg compound per to 0.1 nmol of the nucleic acid,
wherein the nanopiece is positively charged at pH 7-7.5.